Welcome to our dedicated page for CRY news (Ticker: CRY), a resource for investors and traders seeking the latest updates and insights on CRY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRY's position in the market.
CryoLife, Inc. (NYSE: CRY), a leader in medical devices for cardiac and vascular procedures, announced that management will hold one-on-one meetings at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 18, 2021. This event will not feature a webcast.
Based in Atlanta, Georgia, CryoLife specializes in aortic repair and operates in over 100 countries. For more information, visit www.cryolife.com.
CryoLife reported Q3 2021 revenues of $72.2 million, an 11% increase from Q3 2020, with a net income of $10.6 million or $0.26 per share. The non-GAAP net loss was ($1.2) million. CEO Pat Mackin highlighted revenue growth despite headwinds from the Delta variant and a robust performance in the U.S. On-X aortic valve market. The company anticipates FDA approvals for PerClot and PROACT Mitral in 2022 and projects Q4 revenues between $76.5 and $79.5 million. Full-year revenue is expected to be between $296.0 and $299.0 million.
CryoLife (NYSE: CRY) will release its third quarter 2021 financial results on November 4, 2021, after market closure. A teleconference is scheduled for 4:30 p.m. ET, led by Pat Mackin, the company's CEO. Interested parties can participate by dialing 862-298-0702. An audio replay will be available from November 4 to November 11, 2021. Further details, including a copy of the earnings press release, will be accessible on CryoLife's website.
CryoLife, Inc. (NYSE: CRY) announced the appointment of Anthony Semedo to its Board of Directors, effective October 1, 2021. Semedo brings over 40 years of experience in the medical device sector, previously serving as Senior Vice President at Medtronic. His leadership in aortic devices is expected to enhance CryoLife's growth strategy. Chairman Pat Mackin emphasized Semedo's expertise in R&D and regulatory matters as key assets for the company's commitment to positive patient outcomes.
CryoLife, Inc. (NYSE: CRY), a leader in cardiac and vascular surgery, will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 12:30 p.m. ET. This virtual fireside chat will be accessible via CryoLife's website, with a recording available for 90 days post-event. Headquartered in Atlanta, Georgia, CryoLife specializes in medical devices and implantable tissues for aortic disease treatments, marketing products in over 100 countries. For more details, visit www.cryolife.com.
CryoLife, Inc. (NYSE: CRY) announced its participation in two virtual investor conferences. The first is the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, with a presentation starting at 9:30 a.m. ET. A live webcast will be available on CryoLife's website. Additionally, management will engage in the 6th Annual Needham Virtual Med Tech 1x1 Conference on August 16-17, 2021, although there will be no webcast for this event. CryoLife specializes in medical devices for aortic repair, serving over 100 countries.
CryoLife, Inc. (NYSE: CRY) reported strong financial results for Q2 2021, achieving total revenues of $76.1 million, a 42% increase year-over-year. Despite a net loss of ($2.2) million or ($0.06) per share, the company posted non-GAAP net income of $4.8 million, equivalent to $0.12 per share. Growth was driven by new product launches and recovery in procedure volumes. The company anticipates a 7%–10% revenue increase in H2 2021, projecting full-year revenues between $296 million and $300 million.
CryoLife, Inc. (NYSE: CRY) announced the sale of its PerClot product line to Baxter International (NYSE: BAX) for up to $60.8 million. CryoLife will receive up to $45.8 million, while Starch Medical, Inc. will receive up to $15 million. The transaction includes worldwide marketing rights and related assets. CryoLife will also provide transition services and remain responsible for FDA approval efforts. Proceeds will be used for general corporate purposes, contingent obligations, and potential debt repayment.
CryoLife, Inc. (NYSE: CRY), a leader in cardiac and vascular surgery, will announce its second quarter 2021 financial results on July 29, 2021, after market close. A teleconference and live webcast will occur the same day at 4:30 p.m. ET, hosted by CEO Pat Mackin. A replay will be available from July 29 to August 5, 2021. Interested parties can access the live webcast on their Investor Relations website, where the earnings press release will also be posted, detailing financial and statistical information for the quarter.
